Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment

BMC Cancer

Volumn 3, Issue , 2003, Pages

  Bathe, Oliver F ^a   Dalyot Herman, Nava ^b   Malek, Thomas R ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; OVALBUMIN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CELL FUNCTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG SYNTHESIS; DRUG TARGETING; EFFECTOR CELL; EX VIVO STUDY; IMMUNOLOGICAL MEMORY; IN VITRO STUDY; IN VIVO STUDY; MEMORY CELL; MOUSE; NONHUMAN; PHENOTYPE; SOLID TUMOR; THYMOMA; TISSUE SPECIFICITY; TRANSGENIC MOUSE; TREATMENT FAILURE; ANIMAL; C57BL MOUSE; FEMALE; GENETICS; IMMUNOLOGY; MALE; METHODOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; FEMALE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; OVALBUMIN; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; THYMOMA;

EID: 3042800613     PISSN: 14712407     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2407-3-21     Document Type: Article

References (37)

1. Liu B, Podack ER, Allison JP and Malek TR: Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors J Immunol 1996, 156:1117-1125.
2. Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A and Celis E: Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J Immunol 1997, 158:1796-1802.
3. Alexander-Miller MA, Leggatt GR and Berzofsky JA: Selective expansion of high- or low-avidity cytotoxic cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci 1996, 93:4102-4107.
4. Dalyot-Herman N, Bathe OF and Malek TR: Reversal of CD8+ T cell ignorance and induction of anti-tumor immunity by peptide-pulsed antigen presenting cells. J Immunol 2000, 165:6731-6737.
5. Bathe OF, Dalyot-Herman N and Malek TR: IL-2 during in vitro priming promotes subsequent engraftment and successful adoptive tumor immunotherapy bypersistent memory phenotypic CD8+ T cells. J Immunol 2001, 167:4511-4517.
6. Carbone FR, Sterry SJ, Butler J, Rodda S and Moore MW: T cell receptor a-chain pairing determines the specificity of residue 262 within the Kb-restricted, ovalbumin257-264 determinant. Int Immunol 1992, 4:861-867.
7. Moore MW, Carbone FR and Bevan MJ: Introduction of soluble protein into the Class I pathway of antigen processing and presentation. Cell 1988, 54:777-785.
8. Pihlgren M, Dubois PM, Tomkowiak M, Sjogren T and Marvel J: Resting memory CD8+ T cells are hyperreactive to antigenic challenge in vitro. J Exp Med 1996, 184:2141-2151.
9. Curtsinger JM, Lins DC and Mescher MF: CD8+ memory T cells(CD44high, Ly6C+) are more sensitive than naive cells (CD44low, Ly6C-) to TCR/CD8 signaling in response to antigen. J Immunol 1998, 160:3236-3243.
10. Veiga-Fernandes H, Walter U, Bourgeois C, McLean A and Rocha B: Response of naive and memory CD8+ T cells to antigen stimulation in vivo. Nature Immunol 2000, 1:47-53.
11. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D and Levitsky H: Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci 1998, 95:1178-1183.
12. Ye X, McCarrick J, Jewett L and Knowles BB: Timely immunization subverts the development of peripheral nonresponsiveness and suppresses tumor development in simian virus 40 tumor antigen-transgenic mice. Proc Natl Acad Sci USA 1994, 91:3916-3920.
13. Seliger B, Hohne A, Jung D, Kallfelz M, Knuth A, Jaeger E, Bernhard H, Momburg F, Tampe R and Huber C: Expression and function of the peptide transporters in escape variants of human renal cell carcinomas Exp Hematol 1997, 25:608-614.
14. Smith ME, Marsh SG, Bodmer JG, Gelsthorpe K and Bodmer WF: Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia Proc Natl Acad Sci U S A 1989, 86:5557-5561.
15. Schreiber K, Wu TH, Kast WM and Schreiber H: Tracking the common ancestry of antigenically distinct cancer variants Clin Cancer Res 2001, 7:871s-875s..
16. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F and Knuth A: Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo Int J Cancer 1996, 66:470-476.
17. Dudley ME and Roopenian DC: Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthrene-induced mouse sarcoma reveals secondary unique and shared antigens J Exp Med 1996, 184:441-447.
18. Seung S, Urban JL and Schreiber H: A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target J Exp Med 1993, 178:933-940.
19. Urban JL, Kripke ML and Schreiber H: Stepwise immunologic selection of antigenic variants during tumor growth J Immunol 1986, 137:3036-3041.
20. Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA and Restifo NP: Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines Cancer Res 1996, 56:2832-2836.
21. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M and Davis MM: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients Nat Med 1999, 5:677-685.
22. Kerkmann-Tucek A, Banat GA, Cochlovius B and Zoller M: Antigen loss variants of a murine renal cell carcinoma: implications for tumor vaccination Int J Cancer 1998, 77:114-122.
23. Ungefroren H, Voss M, Bernstrff WV, Schmid A, Kremer B and Kaltoff H: Immunological escape mechanisms in pancreatic carcinoma. Ann N Y Acad Sci 1999, 880:243-251.
24. Zaks TZ, Chappell DB, Rosenberg SA and Restifo NP: Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition J Immunol 1999, 162:3273-3279.
25. Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerotti J and Tschopp J: Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996, 274:1363-1366.
26. Boland CR and Ricciardiello L: How many mutations does it take to make a tumor? Proc Natl Acad Sci U S A 1999, 96:14675-14677.
27. Stoler DL, Chen N, Basik M, Kahlenberg MS, Rodriguez-Bigas MA, Petrelli NJ and Anderson GR: The onset and extent of genomic instability in sporadic colorectal tumor progression Proc Natl Acad Sci U S A 1999, 96:15121-15126.
28. Cho KR and Vogelstein B: Genetic alterations in the adenoma - carcinoma sequence Cancer 1992, 70:1727-1731.
29. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001, 344:1031-1037.
30. Smith SG: The polyepitope approach to DNA vaccination Curr Opin Mol Ther 1999, 1:10-15.
31. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P and Vieweg J: Human dendritic cells transfected with renal tumor TNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001, 61:3388-3393.
32. Boczkowski D, Nair SK, Nam J, Lyerly HK and Gilboa E: Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000, 60:1028-1034.
33. Lafreniere R and Rosenberg SA: Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol 1985, 135:4273-4280.
34. Yasumura S, Lin W, Hirabayashi H, Vujanovic NL, Herberman RB and Whiteside TL: Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells. Cancer Res 1994, 54:3808-3816.
35. Prevost-Blondel A, Roth E, Rosenthal FM and Pircher H: Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo J Immunol 2000, 164:3645-3651.
36. Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, Whiteside TL and DeLeo AB: Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants J Immunol 2000, 165:5938-5944.
37. Riker A, Cormier J, Panelli M, Kammula U, Wang E, Abati A, Fetsch P, Lee KH, Steinberg S, Rosenberg S and Marincola F: Immune selection after antigen-specific immunotherapy of melanoma Surgery 1999, 126:112-120.